Core Viewpoint - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Agilon Health, Inc. regarding possible violations of federal securities laws following significant leadership changes and financial disclosures that negatively impacted the company's stock price [1][3]. Company Developments - On August 4, 2025, Agilon Health, Inc. announced the resignation of its President, CEO, and Board Director, Steven Sell, from all positions [3]. - The company released its second-quarter 2025 financial results and withdrew its previously issued full-year 2025 earnings guidance, which surprised the market [3]. - Following these announcements, Agilon's share price fell by more than 27% in after-hours trading [3]. Legal Investigation - The investigation by Johnson Fistel focuses on whether Agilon failed to disclose material information to investors regarding the timing, circumstances, or implications of its leadership transition and guidance withdrawal, potentially violating federal securities laws [3].

Group 1 - Marex Group PLC shares fell over 8% on August 5, 2025, following allegations from a NINGI Research report that the company concealed nearly $1 billion in off-balance-sheet derivatives exposure through a Luxembourg fund [2] - The report claims that Marex Group used the fund to generate non-cash trading profits and inflated operating cash flow by misclassifying structured note issuance as income [2] - Block & Leviton is investigating potential securities law violations by Marex Group and may file an action to recover losses for affected investors [4][6] Group 2 - Investors who purchased Marex Group common stock and experienced a decline in share value may be eligible to recover losses, regardless of whether they sold their investment [3] - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7]

Core Viewpoint - A securities class action lawsuit has been filed against Centene Corporation for allegedly making materially false and misleading statements regarding its business operations and market performance during the specified Class Period from December 12, 2024, to June 30, 2025 [1][2]. Group 1: Allegations Against Centene - The lawsuit claims that Centene's management misrepresented the company's marketplace share, indicating lower-than-expected enrollment and increased market morbidity [2]. - It is alleged that the statements made by Centene's management about the company's business and prospects were materially false and lacked a reasonable basis throughout the Class Period [2]. Group 2: Lead Plaintiff Process - Investors in Centene have until September 8, 2025, to seek appointment as a lead plaintiff, representing the interests of the class in the litigation [3]. - The lead plaintiff is typically the investor or small group of investors with the largest financial interest in the case and who are representative of the class [3]. Group 3: Firm Information - Kessler Topaz Meltzer & Check, LLP is a law firm that prosecutes class actions and has a reputation for recovering billions for victims of corporate misconduct [4]. - The firm encourages Centene investors who have experienced significant losses to contact them for more information regarding the lawsuit [4].

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of Barnes & Noble Education, Inc. regarding potential securities fraud or unlawful business practices [1][3] - The company disclosed a delay in its annual report due to an investigation into the recording of digital sales costs, with early findings suggesting an overstatement of accounts receivable by up to $23 million [3] - Following the news of the investigation, Barnes & Noble's stock price fell by $2.36 per share, or 21.02%, closing at $8.87 per share [4] Company Overview - Barnes & Noble Education, Inc. is facing scrutiny over its financial reporting practices, particularly concerning the accuracy of its accounts receivable [3] - The company expects to report at least one material weakness related to manual journal entries in its financial statements [3] Legal Context - The Pomerantz Firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [5]

Core Viewpoint - Molina Healthcare, Inc. is under investigation for potential securities fraud and unlawful business practices following disappointing financial results and guidance revisions [1][4]. Financial Performance - On July 7, 2025, Molina reported preliminary adjusted earnings of approximately $5.50 per share and lowered its full-year 2025 adjusted earnings guidance by over 10% to a range of $21.50 to $22.50 per share [3]. - Following this announcement, Molina's stock price decreased by $6.97, or about 2.9%, closing at $232.61 per share [3]. - On July 23, 2025, Molina released finalized second-quarter results, reporting adjusted earnings per diluted share of $5.48, which missed both analyst estimates and prior guidance [4]. - The earnings shortfall was attributed to increased medical cost pressures, including higher utilization of behavioral health, pharmacy, and inpatient/outpatient services [4]. - Molina again revised its full-year guidance downward due to updated information and revised assumptions regarding medical cost trends [4]. - Following the finalized results, Molina's stock price fell by $32.03, or approximately 16.8%, closing at $158.22 per share [5].

NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Flywire Corporation (NASDAQ: FLYW) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Flywire, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/flywire-corporation-class-action-lawsuit. Investors have until September 23, 2025, to ask the Court to b ...

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims related to undisclosed challenges in product adoption and a significant decline in stock value following revenue forecast cuts [1][2][4][5][6]. Group 1: Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Group 2: Legal Proceedings - The lawsuit is pending in the U.S. District Court for the Central District of California, titled Makaveev v. RxSight, Inc., et al., No. 25-cv-01596, with investors having until September 22, 2025, to seek lead plaintiff status [2]. Group 3: Financial Performance and Stock Impact - RxSight experienced a significant decline in stock price, dropping approximately 38% from $26.12 to $16.21 per share on April 3, 2025, after cutting its 2025 revenue forecast due to a market softening noted in the second half of 2024 [5]. - Following a further revenue forecast cut on July 8, 2025, attributed to slower LAL utilization and adoption challenges, the stock price fell again by about 38%, from $12.79 to $7.95 per share on July 9, 2025 [6].

Core Viewpoint - Berger Montague PC is investigating claims against Fiserv, Inc. following a class action lawsuit alleging that the company overstated its growth by not disclosing issues with its Clover payment platform [1][3]. Group 1: Lawsuit Details - The class action lawsuit claims that Fiserv and certain executives failed to disclose that Clover's revenue growth was artificially boosted by forcing merchants to transition from the legacy Payeezy platform [3]. - Investors became aware of Fiserv's true financial situation after the company lowered its 2025 organic growth projections on July 23, 2025, leading to a significant decline in share price [4]. Group 2: Investor Information - Investors who purchased Fiserv securities between July 24, 2024, and July 22, 2025, have until September 22, 2025, to seek appointment as lead plaintiff representatives [2][5].

Contact Us To Participate or Learn More: If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us. The Law Offices of Frank R. Cruz, Email us at: [email protected] Call us at: 310-914-5007 Visit our website at: www.frankcruzlaw.com Follow us for updates on Twitter: twitter.com/FRC_LAW. If you inquire by email, please include your mailing address, telephone number, and number of shares p ...

Core Viewpoint - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Fluor Corporation regarding possible violations of federal securities laws following a significant drop in Fluor's stock price after disappointing financial results and lowered guidance [1][3]. Financial Performance - On August 1, 2025, Fluor Corporation reported its second-quarter financial results and lowered its full-year guidance, attributing the disappointing performance to escalating costs across several infrastructure projects, including subcontractor design errors, increased material prices, and scheduling delays [3]. - Fluor also noted a decline in capital spending among customers, which had not been previously disclosed despite earlier affirmations of its full-year outlook [3]. - Following the announcement, Fluor shares closed down 27.04% on August 1, 2025 [3]. Legal Investigation - Johnson Fistel, PLLP is reaching out to investors who incurred significant losses in Fluor securities to determine eligibility for participation in a potential class action or recovery of losses [2].